Quarterly Result14 Nov 2026, 06:50 pm
Aarey Drugs Declares Standalone Unaudited Q2 FY27 Results
AI Summary
Aarey Drugs & Pharmaceuticals Ltd announced its Standalone Unaudited Financial Results for the second quarter and half year ended September 30, 2026. The Board of Directors approved these results along with the Limited Review Report and MD/CFO certification. Additionally, the company approved the Statement of Deviation or Variation in Utilization of Funds Raised through Convertible Warrants (Preferential Issue). The trading window will reopen 48 hours after the announcement of these results.
Key Highlights
- Board approved standalone unaudited financial results for Q2 & H1 FY27.
- Limited Review Report and MD/CFO certification were approved.
- Statement of Deviation/Variation in fund utilization approved.
- Trading window to open 48 hours post-announcement.
Price Impact
More from AAREYDRUGS